Branded Legacy,
Inc. Significantly Expands Asset Portfolio and Production Capacity
Through Successful Acquisition of Sycamore BioPharma,
Inc.
"Company Prepares for Clinical Trials with
Esteemed Addition: Dr. Mark T. Hamann, Endowed Chair of Drug
Discovery and Biomedical Sciences at the MUSC College of
Pharmacy"
Melbourne, FL -- March 12, 2024 -- InvestorsHub NewsWire -- Branded
Legacy (OTC.PK:
BLEG), Inc., a trailblazing BioTech holdings company, proudly
announces the strategic acquisition of Sycamore BioPharma, Inc, a
distinguished developer of plant-based pharmaceuticals. This
strategic milestone not only fortifies Branded Legacy's standing as
a prominent player in the biotech sector but also secures assets
exceeding $2 million, along with key personnel crucial for
advancing clinical trials following this successful union.
Renowned for its meticulous development of wellness solutions,
ranging from gummies to compression sleeves and pain-relieving
topical creams, Sycamore BioPharma has earned acclaim as a prolific
product developer. The acquisition brings forth over $500,000 in
high-quality, ready-to-sell inventory and aligns seamlessly with
Branded Legacy's dedication to quality, authenticity, and a
commitment to natural ingredients.
David Oswald, CEO at Branded Legacy, Inc., expresses enthusiasm
about the acquisition, stating, "Branded Legacy is thrilled to
embrace Sycamore BioPharma into our family of companies. This
tactical move not only compliments our existing portfolio, but also
brings us several steps closer to our goal of achieving FDA
approval for several of our pharmaceutical products.."
The acquisition not only opens new markets for Sycamore
BioPharma but also provides access to Branded Legacy's extensive
network, enhancing the company's ability to connect with consumers,
build brand loyalty, and drive sales growth. It was also a crucial
step in securing and maintaining a slew of large white label
manufacturing and extraction contracts.
Tyler Stone, President of Sycamore Biopharma, Inc., is also
enthusiastic about the acquisition stating, "Branded Legacy brings
significant strengths in areas where Sycamore BioPharma was seeing
significant challenges. Their network and consumer outreach
will undoubtedly drive sales growth of our innovative products and
we are proud to be a part of the Branded Legacy network of
companies."
The collaboration between Branded Legacy and Sycamore BioPharma
is poised to unlock synergies across various business facets.
Leveraging Branded Legacy's web properties, brand management, and
marketing expertise, the integration aims to maximize the reach and
impact of Sycamore BioPharma's groundbreaking wellness solutions.
Furthermore, the addition of Dr. Mark Hamann, a PHD holding
scientist, to Branded Legacy's roster will enhance efforts in
developing novel pharmaceuticals and streamline the FDA approval
process, particularly in clinical trials.
Dr. Mark T. Hamann, the newly appointed Director of Clinical
Trials at Branded Legacy, brings a wealth of expertise as the
Charles and Carol Cooper/SmartState Endowed Chair of Drug Discovery
and Biomedical Sciences at the Medical University of South Carolina
College of Pharmacy. Holding Adjunct appointments with The
University of Maryland's Institute of Marine and Environmental
Technology and the Bigelow Marine Laboratory in Maine, Dr. Hamann's
distinguished career commenced in GMP pharmaceutical manufacturing
at Solvay Pharmaceuticals in Baudette, Minnesota.
Throughout his career, Dr. Hamann has authored over 250
scientific papers, reviews, and book chapters, while mentoring over
100 graduate students, postdoctoral fellows, and visiting scholars.
Dr. Hamann's graduate studies led to the discovery of the
anticancer agent, kahalalide F, which advanced to clinical trials
in collaboration with biotech company PharmaMar. Currently serving
as an Associate Editor for Biochimica et Biophysica Acta, General
Subjects, Dr. Hamann's research group is actively engaged in the
isolation, structure determination, and synthesis optimization of
natural products and toxins. Their focus on plant and invertebrate
microbiomes aligns with Branded Legacy's commitment to sustainable
pharmaceutical development.
Dr. Hamann's ongoing projects include the preclinical
development of a small pipeline of natural products with potential
applications against cancer, emerging infectious diseases, and
neuropsychiatric disorders. His extensive experience and dedication
to advancing scientific frontiers make him a valuable addition to
Branded Legacy's mission to deliver high-quality,
scientifically-backed solutions in the biotech industry.
Branded Legacy has already begun supplying the Medical University
of South Carolina with samples of mitragynine extract in order to
build an effective experimental design for addiction
mitigation. Although these trials are arduous, Branded
Legacy is committed to doing whatever is necessary to support
the process and offer these therapies to the patients who
need them as quickly as possible
In other company news, Branded Legacy has just completed a move
to a significantly larger facility, accommodating the expanding
operations and facilitating enhanced capabilities. The move comes
in tandem with the acquisition of millions of dollars worth of
state-of-the-art scientific and extraction equipment, solidifying
Branded Legacy's commitment to staying at the forefront of
innovation in the biotech industry.
The new facility not only provides increased space for research
and development but also positions Branded Legacy to meet the
rising demand for its innovative wellness solutions. The
acquisition of advanced scientific and extraction equipment further
strengthens the company's technological infrastructure, supporting
its endeavors in drug discovery, pharmaceutical development, and
the optimization of natural products.
For more information about Sycamore BioPharma, Inc, please
visit: https://sycamorebp.com/
Original Copy of this Press Release:
https://brandedlegacy.com/branded-legacy-inc-elevates-biotech-presence-through-successful-acquisition-of-sycamore-biopharma-inc
For media inquiries, please contact:
Investor Relations & Media Contact
Joe Holladay
Branded Legacy
Phone: 321-345-3565
Email: info@brandedlegacy.com
Website: https://brandedlegacy.com/
About Branded Legacy, Inc.:
Branded Legacy, Inc. (OTC:
BLEG) is a diversified holdings company focused on the biotech
sector. With a commitment to excellence and innovation, Branded
Legacy specializes in the development and marketing of cutting-edge
products and services, including ventures in biotechnology, digital
solutions, and wellness products.
Safe Harbor Statement on Forward-Looking Language:
This release includes forward-looking statements, subject to
risks and uncertainties that could cause actual results to differ
materially from current expectations. The company disclaims any
intention or obligation to update or revise forward-looking
statements. Forward-looking statements may be identified by words
such as "may," "will," "expect," "believe," "anticipate,"
"estimate," and similar expressions.
Branded Legacy (PK) (USOTC:BLEG)
Historical Stock Chart
From Oct 2024 to Nov 2024
Branded Legacy (PK) (USOTC:BLEG)
Historical Stock Chart
From Nov 2023 to Nov 2024
